Literature DB >> 23233619

Dos and don'ts in diagnosing antiphospholipid syndrome.

Jacob H Rand1, Lucia R Wolgast.   

Abstract

Antiphospholipid syndrome (APS) is an acquired autoimmune thrombotic tendency that is identified by the presence of abnormal antiphospholipid laboratory tests in patients who have a history of vascular thrombosis and/or pregnancy complications including recurrent spontaneous miscarriages and a group of other complications due to placental insufficiency. Diagnostic testing for APS is often problematic because of many misconceptions regarding these empirically derived assays. This chapter is intended to provide hematology-oncology consultants with practical information about the uses and limitations of assays used to diagnose APS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233619     DOI: 10.1182/asheducation-2012.1.455

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  5 in total

Review 1.  The Laboratory Diagnosis of the Antiphospholipid Syndrome.

Authors:  Jasmina Ahluwalia; Sreejesh Sreedharanunni
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-22       Impact factor: 0.900

Review 2.  Antiphospholipid syndrome: A diagnostic challenge.

Authors:  R S Mallhi; Neerja Kushwaha; T Chatterjee; J Philip
Journal:  Med J Armed Forces India       Date:  2016-06-24

Review 3.  Evidence-based management of recurrent miscarriages.

Authors:  Yadava B Jeve; William Davies
Journal:  J Hum Reprod Sci       Date:  2014-07

4.  Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus.

Authors:  Sara Taveras Alam; Karenza Alexis; Ashwin Sridharan; Marianna Strakhan; Tarek Elrafei; Richard J Gralla; Louis J Reed
Journal:  Case Rep Hematol       Date:  2014-12-07

5.  Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome.

Authors:  Anna Lis-Święty; Ligia Brzezińska-Wcisło; Hubert Arasiewicz; Beata Bergler-Czop
Journal:  Postepy Dermatol Alergol       Date:  2014-04-22       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.